Bausch Health Companies Inc. Restricted Cash and Cash Equivalents, Noncurrent
Bausch Health Companies Inc. (BHC) had Restricted Cash and Cash Equivalents, Noncurrent of $8.23 million as of 2012-09-30, per its 10-Q filed 2012-11-05.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Restricted Cash and Cash Equivalent, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2012-11-05
- 2012-09-30: Restricted Cash and Cash Equivalents, Noncurrent $8.23M.
- 2012-06-30: Restricted Cash and Cash Equivalents, Noncurrent $8.60M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2012-09-30 | $8.23M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $8.60M 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |